66 completed, 24 terminated, 21 recruiting, 15 active not recruiting. 59 Phase 2, 36 Not applicable, 33 Phase 1, 9 Phase 3, 8 Early Phase 1.
Follow Fludeoxyglucose F 18: new trials by email Literature Review of Fludeoxyglucose F 18 trials Research Report on Fludeoxyglucose F 18
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer Best Practice, Biopsy of Breast, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Washington | 22 | 2026-02-26 | 2026-05-19 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801 - Glioblastoma, Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2025-07-28 | 2026-09-18 |
| Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography - Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4 | Phase 1 | Recruiting | City of Hope Medical Center | 27 | 2025-06-17 | 2026-10-22 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 15 | 2024-09-18 | 2026-08-06 |
| Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer Abemaciclib, Anastrozole, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 60 | 2024-07-22 | 2026-09-24 |
| CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-03-28 | 2024-05-01 | |
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-01-23 | 2026-10-14 |
| Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging - Glioma | Completed | OHSU Knight Cancer Institute | 4 | 2023-12-11 | 2026-06-05 | |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-22 |
| Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial Chemotherapy, Computed Tomography, Fludeoxyglucose F-18 - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 235 | 2023-05-10 | 2026-10-19 |
Showing 20 of 142. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (19) · Lung Neoplasms (17) · Breast Neoplasms (16) · Squamous Cell Carcinoma of Head and Neck (10) · Uterine Cervical Neoplasms (9) · Esophageal Neoplasms (7) · Glioblastoma (7) · Rectal Neoplasms (6) · Colorectal Neoplasms (5) · Head and Neck Neoplasms (5) · Lymphoma (5) · Lymphoma, Large B-Cell, Diffuse (5) · Melanoma (5) · Neoplasm Metastasis (5) · Oropharyngeal Neoplasms (5)
National Cancer Institute (NCI) (29) · University of Washington (11) · M.D. Anderson Cancer Center (10) · Jonsson Comprehensive Cancer Center (9) · Memorial Sloan Kettering Cancer Center (8) · City of Hope Medical Center (6) · Case Comprehensive Cancer Center (4) · ECOG-ACRIN Cancer Research Group (4) · Mayo Clinic (4) · Ohio State University Comprehensive Cancer Center (4) · American College of Radiology Imaging Network (3) · Children's Oncology Group (3) · Washington University School of Medicine (3) · Abramson Cancer Center at Penn Medicine (2) · Alliance for Clinical Trials in Oncology (2)
United States (127) · Canada (11) · Puerto Rico (4) · Australia (3) · United Kingdom (3) · China (2) · France (2) · Ireland (2) · Italy (2) · South Korea (2) · Belgium (1) · Germany (1) · Hong Kong (1) · Japan (1) · Netherlands (1)
Hannah Linden (3) · Christina Poh (2) · Dawid Schellingerhout (2) · Jason M Johnson (2) · Johannes Czernin, MD (2) · Manisha Shah (2) · Richard L Wahl, M.D. (2) · Roberto Salvioni, MD (2) · Steven M. Larson, MD (2) · Ahmad Awada, MD, PhD (1) · Allison Betof Warner, MD, PhD (1) · Amol M Takalkar, MD, MS, MBA, FACNM (1) · Andrea Necchi, MD (1) · Andrei Iagaru (1) · Anthony F. Shields, MD, PhD (1)
PMID 30573690, PMID 37505794, PMID 10813118, PMID 14688710, PMID 17634125, PMID 17634488, PMID 17882490, PMID 18355490, PMID 18640307, PMID 22105720, PMID 22819172, PMID 22989664, PMID 23187748, PMID 23344409, PMID 23640206, PMID 24170452, PMID 24309981, PMID 25113840, PMID 26672686, PMID 28911922, PMID 28978463, PMID 30179569, PMID 30642285, PMID 30768363, PMID 31142507, PMID 31174236, PMID 31350329, PMID 32992341, PMID 33027064, PMID 33842889, PMID 33843815, PMID 34172602, PMID 34435552, PMID 34597414, PMID 34895479, PMID 35787017, PMID 36083129, PMID 36185311, PMID 36269154, PMID 36367894, PMID 36858722, PMID 37946201, PMID 38107263, PMID 38197800, PMID 38947228, PMID 38981590, PMID 39058968, PMID 39208372, PMID 39365957, PMID 39673591
P30CA008748 (6), U10CA180820 (6), P30CA015704 (4), P30CA033572 (4), P30CA043703 (4), U10CA180868 (4), U10CA180886 (4), P30CA016672 (3), U01CA079778 (3), U01CA080098 (3), U10CA180821 (3), N01CM62206 (2), N01CM62207 (2), P30CA006973 (2), P30CA015083 (2)